comparemela.com

Latest Breaking News On - University cancer center frankfurt - Page 1 : comparemela.com

Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting

Search jobs 30-Apr-2021 Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting   SYDNEY, AUSTRALIA – 29 April 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its TACTI-002 and INSIGHT-004 studies are scheduled to be presented in three poster presentations during the American Society of Clinical Oncology’s (ASCO) 2021 Annual Meeting, which is taking place online as a virtual meeting this year from 4 – 8 June.

Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion

Investegate |Sanofi Announcements | Sanofi: Sanofi s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members

Sanofi Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members Paris, France – March 3, 2021 – At its meeting on March 3, 2021, Sanofi’s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on April 30, 2021, the appointment of two new Directors, Christian Brandts and Barbara Lavernos, as well as the ratification of appointment by cooptation of Gilles Schnepp and the renewal of the mandates of Fabienne Lecorvaisier and Melanie Lee. Bernard Charlès, whose term of office will expire at the end of the next General Shareholder Meeting, did not wish to stand for re-election in order to avoid conflicts of interest that could arise from the de

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.